Vaksin ebola
Vaksin ebola ialah vaksin yang dikembangkan untuk mencegah penyakit ebola. Vaksin ebola pertama yang mendapat kelulusan dari Pentadbiran Makanan dan Dadah ialah rVSV-ZEBOV pada Disember 2019.[1][2] Vaksin ini digunakan untuk menangani wabak Ebola Kivu berdasarkan protokol penggunan.[3]
.jpg) Seorang peserta penyelidikan menerima calon vaksin ebola | |
| Data klinikal | |
|---|---|
| Nama dagang | Ervebo, Zabdeno, Mvabea |
| Kod ATC | |
| Status perundangan | |
| Status perundangan |
|
| Pengecam | |
| Nombor CAS | |
rVSV-ZEBOV sunting
VSV-EBOV atau rVSV-ZEBOV, dijual dengan jenama dagang Ervebo, ialah vaksin yang dibuat dari virus Vesicular stomatitis yang telah direka secara genetik untuk menghasilkan glikoprotein dari virus Ebola sehingga dapat meningkatkan respons imun terhadap virus tersebut.[4][5] Vaksin ini mendapat kelulusan di Kesatuan Eropah pada November 2019[6] dan Amerika Syarikat pada 2019.[1][7]
Rujukan sunting
- ^ a b "First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response". Pentadbiran Makanan dan Dadah. 19 Disember 2019. Diarkibkan daripada yang asal pada 20 Disember 2019. Dicapai pada 19 Disember 2019.
Rencana ini mengandungi teks dari sumber yang berada dalam domain awam.
- ^ McKee S (23 Disember 2019). "US approves Merck's Ebola vaccine". PharmaTimes Online. Surrey, England: PharmaTimes Media Limited. Dicapai pada 24 Disember 2019.
- ^ Beth Mole (16 April 2019). "As Ebola outbreak rages, vaccine is 97.5% effective, protecting over 90K people". Ars Technica.
- ^ Marzi A, Hanley PW, Haddock E, Martellaro C, Kobinger G, Feldmann H (October 2016). "Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona". The Journal of Infectious Diseases. 214 (suppl 3): S360–66. doi:10.1093/infdis/jiw218. PMC 5050468. PMID 27496978.
- ^ Marzi A, Robertson SJ, Haddock E, Feldmann F, Hanley PW, Scott DP, dll. (August 2015). "Ebola Vaccine. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain". Science. 349 (6249): 739–42. doi:10.1126/science.aab3920. PMID 26249231.
- ^ "Ervebo EPAR". European Medicines Agency (EMA). 12 Disember 2019. Dicapai pada 1 Julai 2020.
- ^ "Ervebo". U.S. Food and Drug Administration (FDA). 19 December 2019. Dicapai pada 1 Julai 2020.
Bacaan lanjut sunting
- Farooq F, Beck K, Paolino KM, Phillips R, Waters NC, Regules JA, Bergmann-Leitner ES (June 2016). "Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine". Scientific Reports. 6: 27944. Bibcode:2016NatSR...627944F. doi:10.1038/srep27944. PMC 4914957. PMID 27323685.
- Sullivan N, Yang ZY, Nabel GJ (September 2003). "Ebola virus pathogenesis: implications for vaccines and therapies". Journal of Virology. 77 (18): 9733–7. doi:10.1128/JVI.77.18.9733-9737.2003. PMC 224575. PMID 12941881.
- Diakite I, Mooring EQ, Velásquez GE, Murray MB (August 2016). "Novel Ordered Stepped-Wedge Cluster Trial Designs for Detecting Ebola Vaccine Efficacy Using a Spatially Structured Mathematical Model". PLOS Neglected Tropical Diseases. 10 (8): e0004866. doi:10.1371/journal.pntd.0004866. PMC 4979980. PMID 27509037.
- Cazares LH, Ward MD, Brueggemann EE, Kenny T, Demond P, Mahone CR, dll. (5 September 2016). "Development of a liquid chromatography high resolution mass spectrometry method for the quantitation of viral envelope glycoprotein in Ebola virus-like particle vaccine preparations". Clinical Proteomics. 13 (1): 18. doi:10.1186/s12014-016-9119-8. PMC 5011338. PMID 27597813.
- Konduru K, Shurtleff AC, Bradfute SB, Nakamura S, Bavari S, Kaplan G (13 September 2016). "Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge". PLOS ONE. 11 (9): e0162446. Bibcode:2016PLoSO..1162446K. doi:10.1371/journal.pone.0162446. PMC 5021345. PMID 27622456.
- Cheng F, Murray JL, Zhao J, Sheng J, Zhao Z, Rubin DH (September 2016). "Systems Biology-Based Investigation of Cellular Antiviral Drug Targets Identified by Gene-Trap Insertional Mutagenesis". PLOS Computational Biology. 12 (9): e1005074. Bibcode:2016PLSCB..12E5074C. doi:10.1371/journal.pcbi.1005074. PMC 5025164. PMID 27632082.
- Olowookere SA, Abioye-Kuteyi EA, Adekanle O (November 2016). "Willingness to participate in Ebola viral disease vaccine trials and receive vaccination by health workers in a tertiary hospital in Ile-Ife, Southwest Nigeria". Vaccine. 34 (47): 5758–5761. doi:10.1016/j.vaccine.2016.10.004. PMID 27751640.
- Pavot V (December 2016). "Ebola virus vaccines: Where do we stand?". Clinical Immunology. 173: 44–49. doi:10.1016/j.clim.2016.10.016. PMID 27910805.
- The Wellcome Trust–CIDRAP Ebola Vaccine Team B (January 2017). Completing the development of Ebola vaccines: current status, remaining challenges, and recommendations. Center for Infectious Disease Research and Policy (CIDRAP) and Wellcome Trust. Diarkibkan (PDF) daripada yang asal pada 18 January 2017. Dicapai pada 18 January 2017.
- Rosales-Mendoza S, Nieto-Gómez R, Angulo C (1 January 2017). "A Perspective on the Development of Plant-Made Vaccines in the Fight against Ebola Virus". Frontiers in Immunology. 8: 252. doi:10.3389/fimmu.2017.00252. PMC 5344899. PMID 28344580.
 | Rencana berkenaan perubatan ini ialah rencana tunas. Anda boleh membantu Wikipedia dengan mengembangkannya. |